The Korean journal of internal medicine

  • 제31권3호
  • /
  • Pages.601-604
  • /
  • 2016
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy

  • Han, Sun Ae (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School) ;
  • Yoon, Young Min (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School) ;
  • Lee, Wan Soo (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School) ;
  • Kim, Yun Sung (Division of Rheumatology, Department of Internal Medicine, Chosun University Medical School) ;
  • Shin, Byung Chul (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School) ;
  • Chung, Jong Hoon (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School) ;
  • Kim, Hyun Lee (Division of Nephrology, Department of Internal Medicine, Chosun University Medical School)
  • 투고 : 2014.09.26
  • 심사 : 2015.03.31
  • 발행 : 2016.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Celik AF, Altiparmak MR, Pamuk GE, Pamuk ON, Tabak F. Association of secondary amyloidosis with common variable immune deficiency and tuberculosis. Yonsei Med J 2005;46:847-850. https://doi.org/10.3349/ymj.2005.46.6.847
  2. Ernandez T, Mayadas TN. Immunoregulatory role of TNF-alpha in inflammatory kidney diseases. Kidney Int 2009;76:262-276. https://doi.org/10.1038/ki.2009.142
  3. Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Effectiveness of etanercept vs. cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2064-2069. https://doi.org/10.1093/rheumatology/kes190
  4. Abdallah E, Waked E. Incidence and clinical outcome of renal amyloidosis: a retrospective study. Saudi J Kidney Dis Transpl 2013;24:950-958. https://doi.org/10.4103/1319-2442.118094
  5. Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic disease. Mod Rheumatol 2014;24:137-143. https://doi.org/10.3109/14397595.2013.854048

피인용 문헌

  1. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis vol.40, pp.1, 2016, https://doi.org/10.1007/s00296-019-04363-z
  2. Secondary Amyloidosis Presenting as Ischemic Proctitis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/6663391